The Justice Department last week issued a new directive for combating fraud that made a point of noting the agency will pursue violations of a federal law that tightly regulates the pharmaceutical industry, STAT reported Wednesday. Typically, the agency has pursued health fraud cases centered on providers, clinics, home health agencies, and hospices. By expressly including the Federal Food, Drug, and Cosmetic Act in the directive, the National Fraud Enforcement Division appears to be placing drug and device makers, among others, more clearly in its crosshairs.
One former DOJ official called it “a subtle but significant expansion of their jurisdiction.” Details of the directive’s scope are thin in the available reporting, and the directive text itself was not independently reviewed.
What is clear is the direction. The administration’s posture toward the pharmaceutical industry has hardened across multiple fronts in the same week: PhRMA is in court over the GLOBE pricing pilot, Section 232 tariffs are landing on imported drugs, and now the Justice Department is flagging the industry as a white-collar enforcement priority. Whether the directive produces new cases or mostly signals intent will determine how much compliance spending follows. For now, the signal alone is worth noting for anyone modeling legal and regulatory risk in the sector.